|
US5981568A
(en)
*
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
ES2098188B1
(es)
*
|
1995-05-11 |
1997-12-16 |
Univ Santiago Compostela |
Desarrollo de nanoparticulas a base de polimeros hidrofilicos.
|
|
US20010009904A1
(en)
*
|
1997-12-30 |
2001-07-26 |
Jon A. Wolff |
Process of delivering a polynucleotide to a cell via the vascular system
|
|
GB2330532A
(en)
*
|
1996-07-10 |
1999-04-28 |
Danbiosyst Uk |
Compositions suitable for delivery of genes to epithelial cells
|
|
US6649192B2
(en)
*
|
1996-07-29 |
2003-11-18 |
Universidade De Santiago De Compostela |
Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
|
|
ES2114502B1
(es)
*
|
1996-07-29 |
1999-07-01 |
Univ Santiago Compostela |
Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
|
|
ATE220559T1
(de)
*
|
1996-10-23 |
2002-08-15 |
Sueddeutsche Kalkstickstoff |
Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten
|
|
US6387700B1
(en)
|
1996-11-04 |
2002-05-14 |
The Reagents Of The University Of Michigan |
Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
|
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
|
EP1275380A1
(de)
*
|
1997-01-30 |
2003-01-15 |
Chiron Corporation |
Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
|
|
EP0860167A1
(de)
*
|
1997-01-30 |
1998-08-26 |
Robert Gurny |
DNA und RNA Wirkstoffderivate in Nanopartikeln
|
|
EP0991403B1
(de)
*
|
1997-01-30 |
2003-04-02 |
Chiron Corporation |
Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
|
|
ATE278397T1
(de)
*
|
1997-03-31 |
2004-10-15 |
Boston Scient Ltd |
Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
|
|
AU7133898A
(en)
*
|
1997-04-18 |
1998-11-13 |
Vertex Pharmaceuticals Incorporated |
Nanosized aspartyl protease inhibitors
|
|
US5885609A
(en)
*
|
1997-05-23 |
1999-03-23 |
Northeastern University |
Biocompatible articles and method for making same
|
|
US6254890B1
(en)
*
|
1997-12-12 |
2001-07-03 |
Massachusetts Institute Of Technology |
Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
|
|
EP1037670B1
(de)
*
|
1997-12-12 |
2003-11-05 |
Max-Delbrück-Centrum Für Molekulare Medizin |
Mittel zur gentherapie von tumorerkrankungen, neurodegenerativen, herzkreislauf- und autoimmunerkrankungen
|
|
US6395253B2
(en)
*
|
1998-04-23 |
2002-05-28 |
The Regents Of The University Of Michigan |
Microspheres containing condensed polyanionic bioactive agents and methods for their production
|
|
KR19990085365A
(ko)
*
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
JP2002519317A
(ja)
*
|
1998-06-29 |
2002-07-02 |
ホワイト、スポット、アクチェンゲゼルシャフト |
薬剤製造のための成長因子の使用
|
|
IL125336A0
(en)
*
|
1998-07-14 |
1999-03-12 |
Yissum Res Dev Co |
Compositions for inhibition and treatment of restinosis
|
|
US7008645B2
(en)
*
|
1998-07-14 |
2006-03-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Method of inhibiting restenosis using bisphosphonates
|
|
AU763975B2
(en)
*
|
1998-07-29 |
2003-08-07 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
|
US7087236B1
(en)
|
1998-09-01 |
2006-08-08 |
Merrion Research I Limited |
Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
|
|
WO2000012124A1
(en)
*
|
1998-09-01 |
2000-03-09 |
Elan Corporation, Plc |
Oral vaccine compositions
|
|
ATE322285T1
(de)
*
|
1998-09-01 |
2006-04-15 |
Elan Corp Plc |
Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
|
|
US6689121B1
(en)
*
|
1998-09-24 |
2004-02-10 |
C. R. Bard, Inc. |
Systems and methods for treating ischemia
|
|
US6458092B1
(en)
|
1998-09-30 |
2002-10-01 |
C. R. Bard, Inc. |
Vascular inducing implants
|
|
US6251079B1
(en)
|
1998-09-30 |
2001-06-26 |
C. R. Bard, Inc. |
Transthoracic drug delivery device
|
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
|
US7521068B2
(en)
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
|
WO2000043044A1
(en)
*
|
1999-01-19 |
2000-07-27 |
The Children's Hospital Of Philadelphia |
Compositions and methods for controlled delivery of virus vectors
|
|
JP2003503308A
(ja)
*
|
1999-02-02 |
2003-01-28 |
セーフサイエンス インコーポレイテッド |
遺伝子治療の送達系及び方法
|
|
CA2361421A1
(en)
|
1999-02-03 |
2000-08-10 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
|
EP1471034A3
(de)
*
|
1999-02-03 |
2005-03-02 |
Biosante Pharmaceuticals, Inc. |
Therapeutische kalzium-phosphat Partikel und Methoden zu deren Herstellung und Verwendung
|
|
WO2000056361A2
(en)
*
|
1999-03-24 |
2000-09-28 |
The Secretary Of State For Defence |
Vaccine composition
|
|
US6620170B1
(en)
|
1999-04-26 |
2003-09-16 |
C. R. Bard, Inc. |
Devices and methods for treating ischemia by creating a fibrin plug
|
|
US6986784B1
(en)
|
1999-05-14 |
2006-01-17 |
C. R. Bard, Inc. |
Implant anchor systems
|
|
US6719805B1
(en)
|
1999-06-09 |
2004-04-13 |
C. R. Bard, Inc. |
Devices and methods for treating tissue
|
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
|
US6277082B1
(en)
|
1999-07-22 |
2001-08-21 |
C. R. Bard, Inc. |
Ischemia detection system
|
|
US6629987B1
(en)
|
1999-07-30 |
2003-10-07 |
C. R. Bard, Inc. |
Catheter positioning systems
|
|
US6855160B1
(en)
|
1999-08-04 |
2005-02-15 |
C. R. Bard, Inc. |
Implant and agent delivery device
|
|
DE19961939A1
(de)
*
|
1999-12-22 |
2001-06-28 |
Cognis Deutschland Gmbh |
Verwendung von nanoskaligen kationischen Verbindungen
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7232421B1
(en)
|
2000-05-12 |
2007-06-19 |
C. R. Bard, Inc. |
Agent delivery systems
|
|
US7527807B2
(en)
|
2000-06-21 |
2009-05-05 |
Cubist Pharmaceuticals, Inc. |
Compositions and methods for increasing the oral absorption of antimicrobials
|
|
US7204847B1
(en)
|
2000-07-28 |
2007-04-17 |
C. R. Bard, Inc. |
Implant anchor systems
|
|
US7829100B2
(en)
|
2000-09-12 |
2010-11-09 |
Teagarden Dirk L |
Pharmaceutical composition having modified carrier
|
|
AUPR011700A0
(en)
|
2000-09-14 |
2000-10-05 |
Austin Research Institute, The |
Composition comprising immunogenic virus sized particles (VSP)
|
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
|
WO2002026212A2
(en)
*
|
2000-09-28 |
2002-04-04 |
Chiron Corporation |
Microparticle compositions and methods for the manufacture thereof
|
|
WO2002061129A2
(en)
*
|
2000-11-15 |
2002-08-08 |
Minerva Biotechnologies Corporation |
Oligonucleotide identifiers
|
|
AU1994402A
(en)
|
2000-11-28 |
2002-06-11 |
Mediummune Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン，エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
|
US6977085B2
(en)
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
|
US6884436B2
(en)
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
|
US6607784B2
(en)
|
2000-12-22 |
2003-08-19 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US7193084B2
(en)
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
|
US6951656B2
(en)
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
|
WO2002094320A1
(en)
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
Therapeutic compositions for repairing chondropathy
|
|
WO2002094321A1
(en)
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
Compositions for promoting healing of bone fracture
|
|
AU2002337692B2
(en)
|
2001-09-26 |
2007-09-13 |
Baxter International Inc. |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
|
US7112340B2
(en)
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
|
FR2836381B1
(fr)
*
|
2002-02-22 |
2004-09-10 |
Oreal |
Nanocapsules a base de polyester polyol, et compositions cosmetiques ou dermatologiques les contenant
|
|
DE10209860A1
(de)
*
|
2002-03-06 |
2003-09-25 |
Hemofarm Konzern A D |
Hydrophobe Nanotropfen mit gebundenen Hämoglobinmolekülen in hydrophiler Phase enthaltene Emulsion als Blutersatzstoff
|
|
WO2003075892A1
(en)
*
|
2002-03-13 |
2003-09-18 |
Novartis Ag |
Pharmaceutical microparticles
|
|
JP2003342196A
(ja)
*
|
2002-05-31 |
2003-12-03 |
Mukku:Kk |
静脈注射用組成物、その製造法およびその製剤
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
EP2283864A1
(de)
*
|
2002-07-16 |
2011-02-16 |
Elan Pharma International Ltd. |
Flüssige Zusammensetzung enthaltend stabilisierte Wirkstoff-Nanopartikeln
|
|
FR2842737B1
(fr)
*
|
2002-07-25 |
2006-01-27 |
Centre Nat Rech Scient |
Particules revetues en surface de hyaluronane ou d'un de ses derives et leur utilisation a titre de vecteurs biologiques pour des matieres actives
|
|
WO2004016750A2
(en)
|
2002-08-14 |
2004-02-26 |
Macrogenics, Inc. |
FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
AU2003263343A1
(en)
|
2002-09-09 |
2004-03-29 |
Trigen Limited |
Boronic acid salts ant their use in the treatment of thromobis
|
|
US7659061B2
(en)
|
2002-11-19 |
2010-02-09 |
Pharmacia & Upjohn Company |
Pharmaceutical compositions having a modified vehicle
|
|
EP2368578A1
(de)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
|
CA2512974A1
(en)
|
2003-01-13 |
2004-07-29 |
Macrogenics, Inc. |
Soluble fc.gamma.r fusion proteins and methods of use thereof
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
KR20050115315A
(ko)
*
|
2003-03-26 |
2005-12-07 |
가부시키가이샤 엘티티 바이오파마 |
약물 전달 및 서방성 약물 방출을 표적으로 하는 정맥 내 나노입자
|
|
KR20110094361A
(ko)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 ｉｌ９ 항체 및 그의 용도
|
|
JP5557415B2
(ja)
|
2003-06-02 |
2014-07-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
|
|
US10517883B2
(en)
|
2003-06-27 |
2019-12-31 |
Zuli Holdings Ltd. |
Method of treating acute myocardial infarction
|
|
ES2232287B1
(es)
*
|
2003-07-04 |
2006-11-01 |
Advanced In Vitro Cell Technologies, S.L. |
Nanoparticulas de derivados polioxietilenados.
|
|
US7326571B2
(en)
|
2003-07-17 |
2008-02-05 |
Boston Scientific Scimed, Inc. |
Decellularized bone marrow extracellular matrix
|
|
US20050048617A1
(en)
|
2003-08-18 |
2005-03-03 |
Medimmune, Inc. |
Humanization of antibodies
|
|
WO2005058961A2
(en)
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
|
US9040090B2
(en)
|
2003-12-19 |
2015-05-26 |
The University Of North Carolina At Chapel Hill |
Isolated and fixed micro and nano structures and methods thereof
|
|
US8263129B2
(en)
|
2003-12-19 |
2012-09-11 |
The University Of North Carolina At Chapel Hill |
Methods for fabricating isolated micro-and nano-structures using soft or imprint lithography
|
|
US20070259047A1
(en)
*
|
2004-02-26 |
2007-11-08 |
Yasuaki Ogawa |
Protein Sustained-Release Microparticle Preparation for Injection and Process for Producing the Same
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
AU2005326322B2
(en)
*
|
2004-07-01 |
2009-02-05 |
Yale University |
Targeted and high density drug loaded polymeric materials
|
|
CA2574709A1
(en)
|
2004-07-21 |
2006-02-02 |
Tulane University Health Sciences Center |
Treatment of renal dysfunction and multiple myeloma using pacap compounds
|
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
US20090041812A1
(en)
|
2004-11-01 |
2009-02-12 |
Bell Steve J D |
Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
|
|
WO2007013893A2
(en)
|
2004-11-15 |
2007-02-01 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
|
|
CN101137700B
(zh)
*
|
2005-03-09 |
2012-07-18 |
东丽株式会社 |
微粒及医药组合物
|
|
EP1869192B1
(de)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Rahmenmischung von antikörpern
|
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
|
AU2006249323B2
(en)
*
|
2005-05-27 |
2012-08-30 |
The University Of North Carolina At Chapel Hill |
Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
|
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
|
KR101406415B1
(ko)
|
2005-07-15 |
2014-06-19 |
미셀 테크놀로지즈, 인코포레이티드 |
제어된 형태의 약물 분말을 함유하는 중합체 코팅
|
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
|
HUE029465T2
(en)
|
2005-08-10 |
2017-02-28 |
Macrogenics Inc |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500353A3
(de)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
|
JP5364870B2
(ja)
|
2005-08-19 |
2013-12-11 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
TWI388344B
(zh)
*
|
2005-08-23 |
2013-03-11 |
Celsion Corp |
儲存奈米微粒調合物之方法
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
PT1976877E
(pt)
|
2005-11-30 |
2014-04-29 |
Abbvie Inc |
Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
|
|
BRPI0619249A2
(pt)
|
2005-11-30 |
2011-09-20 |
Abbott Lab |
anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
|
|
WO2008051245A2
(en)
|
2005-12-02 |
2008-05-02 |
Novartis Ag |
Nanoparticles for use in immunogenic compositions
|
|
WO2007074604A1
(ja)
|
2005-12-26 |
2007-07-05 |
Ltt Bio-Pharma Co., Ltd. |
水溶性非ペプチド性低分子薬物含有ナノ粒子
|
|
US20070166800A1
(en)
*
|
2006-01-13 |
2007-07-19 |
Haixiang Lin |
Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
|
|
WO2007109244A2
(en)
*
|
2006-03-21 |
2007-09-27 |
Morehouse School Of Medicine |
Novel nanoparticles for delivery of active agents
|
|
CA2996768C
(en)
|
2006-04-26 |
2020-12-08 |
Micell Technologies, Inc. |
Coatings containing multiple drugs
|
|
MX2008015771A
(es)
|
2006-06-14 |
2009-01-27 |
Macrogenics Inc |
Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
|
|
AU2007281876B2
(en)
|
2006-06-26 |
2013-09-05 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
|
PL3339445T3
(pl)
|
2006-09-08 |
2020-12-14 |
Abbvie Bahamas Ltd. |
Białka wiążące interleukinę 13
|
|
WO2008032327A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Organic nanoparticles obtained from microemulsions by solvent evaporation
|
|
EP2064335A4
(de)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
|
|
US8529959B2
(en)
|
2006-10-17 |
2013-09-10 |
Carmell Therapeutics Corporation |
Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
|
|
CA2667228C
(en)
|
2006-10-23 |
2015-07-14 |
Micell Technologies, Inc. |
Holder for electrically charging a substrate during coating
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
CN101711137B
(zh)
|
2007-01-08 |
2014-10-22 |
米歇尔技术公司 |
具有可生物降解层的支架
|
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
|
US20080175874A1
(en)
*
|
2007-01-19 |
2008-07-24 |
The Procter & Gamble Company |
Applied care compositions comprising functionalized nano-particles
|
|
DE102007005190A1
(de)
|
2007-01-29 |
2008-07-31 |
Flaig, Rüdiger Marcus, Dr. Dr. |
Selektive Kontaktcytotoxika
|
|
DE102007005191A1
(de)
|
2007-01-29 |
2008-07-31 |
Rüdiger Marcus Dr. Dr. Flaig |
Verbessertes Ktenat zum Arzneimitteltransport
|
|
JP4621218B2
(ja)
*
|
2007-02-09 |
2011-01-26 |
有限会社バイオ研 |
Ｔｈ１誘導剤及びその製造方法
|
|
US10265407B2
(en)
|
2007-02-15 |
2019-04-23 |
Yale University |
Modular nanodevices for smart adaptable vaccines
|
|
ES2552842T3
(es)
|
2007-02-19 |
2015-12-02 |
Marine Polymer Technologies, Inc. |
Composiciones hemostáticas y regímenes terapéuticos
|
|
EP2124952A2
(de)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Verfahren zur behandlung von amyloidosen
|
|
US9433516B2
(en)
|
2007-04-17 |
2016-09-06 |
Micell Technologies, Inc. |
Stents having controlled elution
|
|
WO2008132727A2
(en)
*
|
2007-04-26 |
2008-11-06 |
Technion Research And Development Foundation Ltd |
Oral delivery of proteins and peptides
|
|
WO2008148013A1
(en)
|
2007-05-25 |
2008-12-04 |
Micell Technologies, Inc. |
Polymer films for medical device coating
|
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
|
CA2691434C
(en)
|
2007-06-21 |
2020-07-21 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
WO2009049089A1
(en)
|
2007-10-09 |
2009-04-16 |
Washington University In St. Louis |
Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
|
|
CN101868180A
(zh)
|
2007-10-09 |
2010-10-20 |
圣路易斯华盛顿州立大学 |
成像粒子
|
|
DE102007054049A1
(de)
|
2007-11-13 |
2009-05-14 |
Flaig, Rüdiger Marcus, Dr. Dr. |
Arzneimitteltransportsystem zur Bekämpfung von Trypanosomen
|
|
KR100961880B1
(ko)
*
|
2007-12-12 |
2010-06-09 |
중앙대학교 산학협력단 |
밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
|
|
ES2613963T3
(es)
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Anticuerpos manipulados con cisteína para conjugación específica de sitio
|
|
US20110070284A1
(en)
*
|
2008-02-22 |
2011-03-24 |
Musculoskeletal Transplant Foundation |
Biologic matrices comprising anti-infective methods and compositions related thereto
|
|
CN101932311B
(zh)
|
2008-02-22 |
2014-07-16 |
东丽株式会社 |
微粒及其药物组合物
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
JP5608160B2
(ja)
|
2008-04-17 |
2014-10-15 |
ミセル テクノロジーズ、インコーポレイテッド |
生体吸収性の層を有するステント
|
|
ES2498091T3
(es)
*
|
2008-04-28 |
2014-09-24 |
Novartis Ag |
Procedimiento para producir nanopartículas
|
|
JP5646457B2
(ja)
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
KR101005562B1
(ko)
|
2008-05-01 |
2011-01-05 |
한국생명공학연구원 |
난용성 약물을 함유하는 균일한 크기의 고분자 나노입자제조방법
|
|
RU2518351C2
(ru)
|
2008-05-09 |
2014-06-10 |
Эббви Дойчланд Гмбх Унд Ко.Кг, |
Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
|
|
EP3002299A1
(de)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
|
PE20100054A1
(es)
|
2008-06-03 |
2010-03-03 |
Abbott Lab |
Inmunoglobulina con dominio variable dual
|
|
WO2010005726A2
(en)
|
2008-06-16 |
2010-01-14 |
Bind Biosciences Inc. |
Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
|
|
EP2309991B1
(de)
|
2008-06-16 |
2019-03-06 |
Pfizer Inc |
Therapeutische polymernanopartikel mit vincaalkaloiden sowie verfahren zu ihrer herstellung und verwendung
|
|
EA020954B1
(ru)
|
2008-06-16 |
2015-03-31 |
Бинд Терапьютикс, Инк. |
Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
|
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
EP2313122B1
(de)
|
2008-07-17 |
2019-03-06 |
Micell Technologies, Inc. |
Medizinische wirkstofffreisetzungsvorrichtung
|
|
EP2366386A4
(de)
|
2008-10-28 |
2013-11-27 |
Univ Santiago Compostela |
Aus anionischen polymeren hergestellte nanoteilchenförmige systeme
|
|
WO2010068866A2
(en)
|
2008-12-12 |
2010-06-17 |
Bind Biosciences |
Therapeutic particles suitable for parenteral administration and methods of making and using same
|
|
EP2379064B1
(de)
|
2008-12-15 |
2020-02-26 |
Pfizer Inc. |
Lange zirkulierende nanoteilchen zur verzögerten freisetzung von therapeutischen mitteln
|
|
ES2733067T3
(es)
|
2008-12-19 |
2019-11-27 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
|
US8834913B2
(en)
|
2008-12-26 |
2014-09-16 |
Battelle Memorial Institute |
Medical implants and methods of making medical implants
|
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
|
TW201613969A
(en)
|
2009-03-05 |
2016-04-16 |
Abbvie Inc |
IL-17 binding proteins
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
JP2012522589A
(ja)
|
2009-04-01 |
2012-09-27 |
ミシェル テクノロジーズ，インコーポレイテッド |
被覆ステント
|
|
WO2010138192A2
(en)
|
2009-05-27 |
2010-12-02 |
Selecta Biosciences, Inc. |
Nanocarriers possessing components with different rates of release
|
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
|
EP2453834A4
(de)
|
2009-07-16 |
2014-04-16 |
Micell Technologies Inc |
Medizinische wirkstofffreisetzungsvorrichtung
|
|
US9919072B2
(en)
|
2009-08-21 |
2018-03-20 |
Novan, Inc. |
Wound dressings, methods of using the same and methods of forming the same
|
|
CA3062005C
(en)
|
2009-08-21 |
2022-02-15 |
Novan, Inc. |
Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
|
|
US8623358B2
(en)
|
2009-08-29 |
2014-01-07 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
|
AR078254A1
(es)
|
2009-09-01 |
2011-10-26 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2768968A1
(en)
*
|
2009-09-29 |
2011-04-07 |
Eyegate Pharmaceuticals, Inc. |
Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
AU2010303415B2
(en)
|
2009-10-07 |
2015-02-19 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
MX2012004415A
(es)
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
US9216145B2
(en)
|
2009-10-27 |
2015-12-22 |
The Procter & Gamble Company |
Semi-permanent cosmetic concealer
|
|
US9237992B2
(en)
|
2009-10-27 |
2016-01-19 |
The Procter & Gamble Company |
Two-step mascara product
|
|
US10034829B2
(en)
|
2010-10-27 |
2018-07-31 |
Noxell Corporation |
Semi-permanent mascara compositions
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
|
US8916517B2
(en)
|
2009-11-02 |
2014-12-23 |
The Administrators Of The Tulane Educational Fund |
Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
|
|
KR20120118002A
(ko)
|
2009-12-08 |
2012-10-25 |
애보트 게엠베하 운트 콤파니 카게 |
망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
|
|
TR201906255T4
(tr)
|
2009-12-11 |
2019-05-21 |
Pfizer |
Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
|
|
ES2780156T3
(es)
|
2009-12-15 |
2020-08-24 |
Pfizer |
Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
|
|
EP2512452B1
(de)
*
|
2009-12-17 |
2018-09-19 |
The Washington University |
Antithrombotisches nanopartikel
|
|
US9808500B2
(en)
|
2009-12-17 |
2017-11-07 |
Washington University |
Antithrombotic nanoparticle
|
|
EP2531140B1
(de)
|
2010-02-02 |
2017-11-01 |
Micell Technologies, Inc. |
Stent und stenteinsatzsystem mit verbesserter einsetzbarkeit
|
|
JP5835741B2
(ja)
|
2010-02-26 |
2015-12-24 |
国立大学法人 長崎大学 |
抗原または薬物送達複合体
|
|
EP2542582A4
(de)
|
2010-03-02 |
2013-12-04 |
Abbvie Inc |
Therapeutische dll4-bindende proteine
|
|
US8795762B2
(en)
|
2010-03-26 |
2014-08-05 |
Battelle Memorial Institute |
System and method for enhanced electrostatic deposition and surface coatings
|
|
JP2013527157A
(ja)
|
2010-04-15 |
2013-06-27 |
ワシントン・ユニバーシティ |
プロドラッグ組成物、プロドラッグナノ粒子およびその使用方法
|
|
EP2558494B1
(de)
|
2010-04-15 |
2018-05-23 |
AbbVie Inc. |
Amyloid-beta-bindende proteine
|
|
US10232092B2
(en)
|
2010-04-22 |
2019-03-19 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
|
US9004791B2
(en)
|
2010-04-30 |
2015-04-14 |
The Procter & Gamble Company |
Package for multiple personal care compositions
|
|
CA2798432A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
|
EA201291181A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
|
AU2011252883B2
(en)
|
2010-05-14 |
2015-09-10 |
Abbvie Inc. |
IL-1 binding proteins
|
|
CN102905728B
(zh)
|
2010-05-26 |
2015-11-25 |
西莱克塔生物科技公司 |
具有不偶合的佐剂的纳米载体组合物
|
|
US20110318421A1
(en)
*
|
2010-06-24 |
2011-12-29 |
Edward E. Parsonage |
Surface functionalized ceramic nanoparticles
|
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2593039B1
(de)
|
2010-07-16 |
2022-11-30 |
Micell Technologies, Inc. |
Medizinische wirkstofffreisetzungsvorrichtung
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
MX339622B
(es)
|
2010-08-02 |
2016-06-02 |
Macrogenics Inc |
Diacuerpos covalentes y sus usos.
|
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
CN105348387B
(zh)
|
2010-08-14 |
2020-08-25 |
Abbvie 公司 |
β淀粉样蛋白结合蛋白
|
|
WO2012024650A2
(en)
|
2010-08-19 |
2012-02-23 |
Abbott Laboratories |
Anti-ngf antibodies and their use
|
|
SG187908A1
(en)
|
2010-08-20 |
2013-03-28 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
PH12013500337A1
(en)
|
2010-08-26 |
2017-08-23 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
US9572880B2
(en)
|
2010-08-27 |
2017-02-21 |
Sienna Biopharmaceuticals, Inc. |
Ultrasound delivery of nanoparticles
|
|
HUE038539T2
(hu)
|
2010-08-27 |
2018-10-29 |
Sienna Biopharmaceuticals Inc |
Készítmények eljárások célzott hõmodulációhoz
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
US8591876B2
(en)
|
2010-12-15 |
2013-11-26 |
Novan, Inc. |
Methods of decreasing sebum production in the skin
|
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Ｉｌ－１結合蛋白
|
|
CA2823355C
(en)
*
|
2010-12-30 |
2017-08-22 |
Micell Technologies, Inc. |
Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore
|
|
WO2012105224A1
(ja)
*
|
2011-01-31 |
2012-08-09 |
オリンパス株式会社 |
ワクチン・アジュバント
|
|
WO2012118829A2
(en)
|
2011-02-28 |
2012-09-07 |
Novan, Inc. |
Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
KR20140041505A
(ko)
|
2011-04-29 |
2014-04-04 |
셀렉타 바이오사이언시즈, 인크. |
조절 b 세포 유도를 위한 관용원성 합성 나노운반체
|
|
US9173824B2
(en)
|
2011-05-17 |
2015-11-03 |
The Procter & Gamble Company |
Mascara and applicator
|
|
EA201391753A1
(ru)
|
2011-05-21 |
2014-08-29 |
Макродженикс, Инк. |
Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
|
|
WO2012166819A1
(en)
|
2011-05-31 |
2012-12-06 |
Micell Technologies, Inc. |
System and process for formation of a time-released, drug-eluting transferable coating
|
|
RU2640025C2
(ru)
|
2011-07-13 |
2017-12-25 |
Эббви Инк. |
Способы и композиции для лечения астмы с использованием антител против il-13
|
|
CA2841360A1
(en)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
US20130028857A1
(en)
|
2011-07-29 |
2013-01-31 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
|
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
|
BR112014006929A2
(pt)
|
2011-09-23 |
2017-04-04 |
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa |
agentes anti-fator de necrose tumoral-alfa e seus usos
|
|
AU2012326010B2
(en)
*
|
2011-10-18 |
2017-05-11 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
EP2771360A1
(de)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Gegen sclerostin gerchtet immunbinder
|
|
KR102083957B1
(ko)
|
2011-12-05 |
2020-03-04 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
JP2015500829A
(ja)
|
2011-12-05 |
2015-01-08 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
|
|
EP2791175A2
(de)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
|
CN104144947B
(zh)
|
2011-12-14 |
2017-10-27 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗铁相关病症的组合物和方法
|
|
EP3539982B1
(de)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
|
EP3369746A1
(de)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
|
|
US20130195752A1
(en)
|
2012-02-01 |
2013-08-01 |
Regents Of The University Of Minnesota |
Functionalized nanoparticles and methods of use thereof
|
|
KR101880675B1
(ko)
*
|
2012-03-14 |
2018-07-20 |
인제대학교 산학협력단 |
천연 수용성 고분자로 표면 개질된 생분해성 합성 고분자를 포함하는 조직 재생용 칩의 제조 방법 및 이에 의하여 제조된 조직 재생용 칩
|
|
WO2013163176A1
(en)
|
2012-04-23 |
2013-10-31 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
|
WO2013173452A2
(en)
|
2012-05-15 |
2013-11-21 |
The Procter & Gamble Company |
Method for quantitatively determining eyelash clumping
|
|
SG11201407017WA
(en)
|
2012-06-04 |
2014-12-30 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ｎｇｆ抗体およびその方法
|
|
US20140148671A1
(en)
*
|
2012-07-05 |
2014-05-29 |
Empire Technology Development Llc |
Compositions and methods for detecting anastomosis leakage
|
|
TW201402608A
(zh)
|
2012-07-12 |
2014-01-16 |
Abbvie Inc |
Ｉｌ－１結合蛋白質
|
|
EP2895156B1
(de)
|
2012-09-17 |
2019-05-08 |
Pfizer Inc. |
Verfahren zur herstellung therapeutischer nanopartikel
|
|
JP6325552B2
(ja)
|
2012-10-11 |
2018-05-16 |
ナノコンポジックス，インコーポレイテッド |
銀ナノプレート組成物および方法
|
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
|
KR20150082503A
(ko)
|
2012-11-09 |
2015-07-15 |
화이자 인코포레이티드 |
혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
|
|
JP2016509582A
(ja)
|
2012-12-19 |
2016-03-31 |
アンプリミューン， インコーポレイテッド |
抗ヒトｂ７−ｈ４抗体およびその使用
|
|
BR112015014621A2
(pt)
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
Anticorpos anti-h7cr
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
CA2900755C
(en)
|
2013-02-08 |
2021-07-20 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
EP2967803B1
(de)
|
2013-03-12 |
2023-12-27 |
Micell Technologies, Inc. |
Bioabsorbierbare biomedizinische implantate
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
|
JP6505076B2
(ja)
|
2013-03-14 |
2019-04-24 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
|
|
EP2970947A4
(de)
|
2013-03-14 |
2016-10-12 |
Abbott Lab |
Rekombinante hcv-ns3-antigene und mutanten für den verbesserten nachweis von antikörpern
|
|
JP2016514130A
(ja)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Ｎｏｔｃｈ３に対する抗体
|
|
US9993427B2
(en)
|
2013-03-14 |
2018-06-12 |
Biorest Ltd. |
Liposome formulation and manufacture
|
|
BR112015021134A2
(pt)
|
2013-03-15 |
2017-10-10 |
Novartis Ag |
conjugados de fármaco e anticorpo
|
|
EP2970459A2
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
KR102233251B1
(ko)
|
2013-04-03 |
2021-03-26 |
엔-폴드 엘엘씨 |
신규 나노입자 조성물
|
|
BR112015027291A8
(pt)
|
2013-05-03 |
2019-12-24 |
Selecta Biosciences Inc |
uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
|
|
EP2996629B1
(de)
|
2013-05-15 |
2021-09-22 |
Micell Technologies, Inc. |
Bioabsorbierbare biomedizinische implantate
|
|
MX376808B
(es)
|
2013-05-24 |
2025-03-07 |
Medimmune Llc |
Anticuerpos anti-b7-h5 y sus usos.
|
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
|
PE20160930A1
(es)
|
2013-09-16 |
2016-09-03 |
Astrazeneca Ab |
Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
|
|
JP2016533318A
(ja)
|
2013-09-17 |
2016-10-27 |
ユニバーシティ ヘルス ネットワーク （ユーエイチエヌ）： テクノロジー ディベロップメント アンド コマーシャリゼーション |
Ｒｇｍａ／ネオジェニンのシス相互作用又は脂質ラフトを標的とする剤及び治療方法における該剤の使用
|
|
WO2015058868A1
(en)
|
2013-10-25 |
2015-04-30 |
Pangaea Biotech, S.L. |
Compositions and methods for the treatment of cancer
|
|
EP3068801A1
(de)
|
2013-11-13 |
2016-09-21 |
Pfizer Inc. |
Tumornekrosefaktorähnliche ligand-1a-spezifische antikörper sowie zusammensetzungen damit und verwendungen davon
|
|
WO2015084883A2
(en)
|
2013-12-02 |
2015-06-11 |
Abbvie, Inc. |
Compositions and methods for treating osteoarthritis
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
PL3097122T3
(pl)
|
2014-01-24 |
2020-10-19 |
Ngm Biopharmaceuticals, Inc. |
Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
|
|
KR20160135190A
(ko)
|
2014-02-14 |
2016-11-25 |
앤드류 에스. 카이 |
혈관형성 암의 치료를 위한 개선된 방법
|
|
EP3450571B1
(de)
|
2014-02-24 |
2023-04-05 |
Celgene Corporation |
Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
WO2015138337A1
(en)
|
2014-03-09 |
2015-09-17 |
Abbvie, Inc. |
Compositions and methods for treating rheumatoid arthritis
|
|
CN106659800A
(zh)
|
2014-03-12 |
2017-05-10 |
诺华股份有限公司 |
用于修饰抗体以制备免疫缀合物的特定位点
|
|
ES2834927T3
(es)
|
2014-03-14 |
2021-06-21 |
Pfizer |
Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
|
|
TW202214691A
(zh)
|
2014-03-21 |
2022-04-16 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
|
EP3142700B1
(de)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
|
|
WO2015179602A1
(en)
*
|
2014-05-21 |
2015-11-26 |
Albert Einstein College Of Medicine, Inc. |
Compositions and methods for enhancing red blood cell storage time and survivability using nitric oxide releasing hybrid hydrogel nanoparticles
|
|
SG10201913680PA
(en)
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
JP6755235B2
(ja)
|
2014-07-16 |
2020-09-16 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
低悪性度漿液性癌におけるｈｅｒ３阻害
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
PE20170903A1
(es)
|
2014-08-12 |
2017-07-12 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6
|
|
WO2016037164A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
|
|
AP2017009823A0
(en)
|
2014-09-26 |
2017-03-31 |
Macrogenics Inc |
Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
|
|
PE20170912A1
(es)
|
2014-11-14 |
2017-07-12 |
Novartis Ag |
Conjugados de anticuerpo-farmaco
|
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
CN107205940A
(zh)
|
2014-12-15 |
2017-09-26 |
约翰霍普金斯大学 |
舒尼替尼制剂及其在治疗眼部疾病中的使用方法
|
|
WO2016118921A1
(en)
|
2015-01-24 |
2016-07-28 |
Abbvie, Inc. |
Compositions and methods for treating psoriatic arthritis
|
|
HK1247215A1
(zh)
|
2015-01-26 |
2018-09-21 |
Macrogenics, Inc. |
包含dr5-结合结构域的多价分子
|
|
KR102740384B1
(ko)
|
2015-03-03 |
2024-12-06 |
키맵 리미티드 |
항체, 용도 및 방법
|
|
RU2715597C2
(ru)
|
2015-05-29 |
2020-03-02 |
Эббви Инк. |
Антитела к cd40 и способы их применения
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CA2987209A1
(en)
*
|
2015-06-10 |
2016-12-15 |
Evonik Rohm Gmbh |
Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2016205010A1
(en)
*
|
2015-06-19 |
2016-12-22 |
The Regents Of The University Of California |
Treating vasculature related diseases or disorders using nanoparticles
|
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
|
AU2016298227B9
(en)
|
2015-07-30 |
2019-10-31 |
Macrogenics, Inc. |
PD-1-binding molecules and methods of use thereof
|
|
KR101709628B1
(ko)
*
|
2015-09-10 |
2017-02-24 |
한국과학기술연구원 |
개질된 생분해성 고분자의 제조 방법, 그에 의해 제조된 개질된 생분해성 고분자 및 이를 이용한 생분해성 스텐트
|
|
BR112018004867A2
(pt)
|
2015-09-11 |
2018-10-16 |
Abbvie Deutschland |
métodos para tratamento das formas recorrentes de esclerose múltipla
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
EP3355920A4
(de)
|
2015-09-29 |
2019-05-15 |
Celgene Corporation |
Pd-1-bindende proteine und verfahren zur verwendung davon
|
|
WO2017070578A1
(en)
|
2015-10-21 |
2017-04-27 |
The Regents Of The University Of Michigan |
Detection and treatment of caries and microcavities with nanoparticles
|
|
WO2017070561A1
(en)
|
2015-10-23 |
2017-04-27 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
HK1257499A1
(zh)
*
|
2015-11-12 |
2019-10-25 |
Graybug Vision, Inc. |
用於治疗的聚集性微粒
|
|
EP3383908A1
(de)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
|
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
|
JP6955507B2
(ja)
|
2015-12-14 |
2021-10-27 |
マクロジェニクス，インコーポレーテッド |
Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
|
|
EP3405492B1
(de)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
|
WO2017172437A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Tufts University |
Fabrication of macroporous polymeric hydrogel microparticles
|
|
TWI762487B
(zh)
|
2016-06-08 |
2022-05-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
|
EP3468598A1
(de)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98-antikörper und antikörper-wirkstoff-konjugate
|
|
CA3027044A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
EP3515943A4
(de)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
|
|
WO2018053405A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
MX2019003988A
(es)
*
|
2016-10-10 |
2019-08-14 |
Abraxis Bioscience Llc |
Formulaciones de nanoparticulas y sus metodos de fabricacion y uso.
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
EP3544628A4
(de)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1bb-bindende proteine und verwendungen davon
|
|
US11684583B2
(en)
|
2016-12-08 |
2023-06-27 |
Massachusetts Institute Of Technology |
Compositions and related methods for targeted drug delivery
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
KR102753928B1
(ko)
|
2017-03-11 |
2025-01-14 |
셀렉타 바이오사이언시즈, 인크. |
항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
|
|
AU2018240462C1
(en)
|
2017-03-23 |
2022-12-08 |
Graybug Vision, Inc. |
Drugs and compositions for the treatment of ocular disorders
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
CN111201040A
(zh)
|
2017-05-10 |
2020-05-26 |
灰色视觉公司 |
用于医学疗法的缓释微粒及其悬浮液
|
|
KR20250036941A
(ko)
|
2017-05-31 |
2025-03-14 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
EP3635007A1
(de)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Verfahren zur behandlung von krebs unter verwendung von antikörpern und molekülen, die an btn1a1 oder btn1a1-liganden binden
|
|
JP6865491B2
(ja)
*
|
2017-07-25 |
2021-04-28 |
レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． |
血管内生理活性物質送達用組成物
|
|
CA3083363A1
(en)
|
2017-12-01 |
2019-06-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
BR112020010753A2
(pt)
|
2017-12-01 |
2020-11-24 |
The Regents Of The University Of California |
anticorpos anti-cxcr5 e composições e usos dos mesmos
|
|
MX2020009526A
(es)
|
2018-03-12 |
2020-10-28 |
Zoetis Services Llc |
Anticuerpos anti-ngf y metodos de estos.
|
|
KR102088663B1
(ko)
*
|
2018-03-20 |
2020-03-13 |
한국세라믹기술원 |
친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도
|
|
CA3094756A1
(en)
|
2018-03-29 |
2019-10-03 |
Pfizer Inc. |
Lfa3 variants and compositions and uses thereof
|
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
EP3784705A4
(de)
*
|
2018-04-23 |
2022-03-02 |
Graybug Vision, Inc. |
Verbesserte kontinuierliche mikropartikelherstellung
|
|
CN112165974B
(zh)
|
2018-05-31 |
2024-11-08 |
诺华股份有限公司 |
乙型肝炎抗体
|
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
EP3807321A4
(de)
|
2018-06-18 |
2022-03-02 |
Anwita Biosciences, Inc. |
Anti-mesothelin-konstrukte und verwendungen davon
|
|
IL280199B2
(en)
|
2018-07-20 |
2025-08-01 |
Pf Medicament |
Receptor for vista
|
|
US11359024B2
(en)
|
2018-09-07 |
2022-06-14 |
Pfizer Inc. |
Anti-AVB8 antibodies and compositions and uses thereof
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
TW202028237A
(zh)
|
2018-09-27 |
2020-08-01 |
美商西建公司 |
SIRPα結合蛋白及其使用方法
|
|
US12492250B2
(en)
|
2018-09-28 |
2025-12-09 |
Emory University |
suPAR and prediction and treatment of acute kidney injury
|
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗ＴＮＦ－α抗體
|
|
PH12021551479A1
(en)
|
2018-12-21 |
2022-07-18 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
|
WO2020158833A1
(ja)
|
2019-01-31 |
2020-08-06 |
セルメディシン株式会社 |
無機塩類タンパク複合医療機器
|
|
KR102563319B1
(ko)
|
2019-03-08 |
2023-08-03 |
앱티스 주식회사 |
위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
|
|
WO2020205827A1
(en)
|
2019-04-01 |
2020-10-08 |
Rush University Medical Center |
Reagents and assays using modified integrin domains
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
EP3980784A1
(de)
|
2019-06-04 |
2022-04-13 |
Selecta Biosciences, Inc. |
Formulierungen und dosen von pegylierter uricase
|
|
EP4004214A1
(de)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Gentechnisch hergestelltes nukleinsäureregulationselement und verwendungsverfahren dafür
|
|
CN114729045B
(zh)
|
2019-09-26 |
2025-09-09 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
|
CN114829404B
(zh)
|
2019-10-09 |
2025-09-09 |
斯特库比公司 |
对糖基化的lag3特异的抗体及其使用方法
|
|
JP7600528B2
(ja)
*
|
2020-03-16 |
2024-12-17 |
株式会社リコー |
粒子の製造方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
|
US20230167193A1
(en)
|
2020-05-01 |
2023-06-01 |
Novartis Ag |
Immunoglobulin variants
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
CN116157510A
(zh)
|
2020-06-17 |
2023-05-23 |
詹森生物科技公司 |
用于制造多能干细胞的材料和方法
|
|
WO2022012680A1
(en)
|
2020-07-16 |
2022-01-20 |
Nanjing Legend Biotech Co., Ltd. |
Cd20 binding molecules and uses thereof
|
|
WO2022031576A1
(en)
|
2020-08-03 |
2022-02-10 |
Janssen Biotech, Inc. |
Materials and methods for multidirectional biotransportation in virotherapeutics
|
|
CA3190987A1
(en)
|
2020-08-10 |
2022-02-17 |
Janssen Biotech, Inc. |
Materials and methods for producing bioengineered virus specific lymphocytes
|
|
CN114073791B
(zh)
*
|
2020-08-21 |
2022-05-31 |
中国科学院化学研究所 |
一种软骨组织工程支架及其制备方法与应用
|
|
WO2022072597A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Diomics Corporation |
Transdermal medicament delivery device
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
AU2021356667A1
(en)
|
2020-10-07 |
2023-06-08 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Ｆｃ変異体
|
|
AU2021374083A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
EP4240491A1
(de)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19-bindende moleküle und verwendungen davon
|
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ， インコーポレイテッド |
高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
US12404439B2
(en)
|
2021-03-29 |
2025-09-02 |
Championx Llc |
Extended release asphaltene inhibitor composition
|
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
EP4413018A1
(de)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Rekombinante adeno-assoziierte viren zur gezielten abgabe
|
|
EP4413019A2
(de)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Rekombinante adeno-assoziierte viren zur zns-tropen verabreichung
|
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
CN118119642A
(zh)
|
2021-10-28 |
2024-05-31 |
诺华股份有限公司 |
工程化Fc变体
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
CA3251397A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
METHODS AND COMPOSITIONS COMPRISING COMPONENTS FOR BRINGING BISORPOSE VΒ17 T LYMPHOCYTES TO CONTACT WITH BIOMODIFIED VIRUS-SPECIFIC LYMPHOCYTES
|
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20250277004A1
(en)
|
2022-04-18 |
2025-09-04 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
|
EP4554969A1
(de)
|
2022-07-15 |
2025-05-21 |
Janssen Biotech, Inc. |
Material und verfahren zur verbesserten biotechnologischen paarung antigenbindender variabler regionen
|
|
CN115006605A
(zh)
*
|
2022-07-20 |
2022-09-06 |
苏州中天医疗器械科技有限公司 |
一种药物涂层球囊及其制备方法和应用
|
|
US20250188492A1
(en)
|
2022-07-22 |
2025-06-12 |
Janssen Biotech, Inc. |
Enhanced Transfer of Genetic Instructions to Effector Immune Cells
|
|
JP2025525969A
(ja)
|
2022-08-05 |
2025-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
脳腫瘍を治療するためのｃｄ９８結合構築物
|
|
CA3263784A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
TRANSFERRIN RECEPTOR BINDING PROTEINS FOR THE TREATMENT OF BRAIN TUMORS
|
|
US20260055144A1
(en)
|
2022-08-24 |
2026-02-26 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
EP4594442A1
(de)
*
|
2022-09-28 |
2025-08-06 |
ChampionX LLC |
Asphalteninhibitorzusammensetzung mit verlängerter freisetzung
|
|
JP2025534666A
(ja)
|
2022-10-11 |
2025-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
|
CN116211732B
(zh)
*
|
2023-01-03 |
2023-11-17 |
广州澳特朗生物技术有限公司 |
一种具有组织修护、抗皱和舒缓功效的纤连蛋白纳米制剂及其制备方法和应用
|
|
TW202448505A
(zh)
|
2023-03-01 |
2024-12-16 |
美商普泛森生技公司 |
用於治療第1型糖尿病的方法及組成物
|
|
TW202506177A
(zh)
|
2023-03-30 |
2025-02-16 |
美商普泛森生技公司 |
減少外源性胰島素使用之方法
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
AU2024299422A1
(en)
|
2023-07-27 |
2026-03-12 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
CN116874996B
(zh)
*
|
2023-09-01 |
2023-12-05 |
山东龙兴塑膜科技股份有限公司 |
一种改性聚酯的制备方法及在覆膜铁用聚酯薄膜中的应用
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025262564A1
(en)
|
2024-06-17 |
2025-12-26 |
Pfizer Inc. |
Use of anti-cxcr5 antibodies
|
|
WO2026058155A1
(en)
|
2024-09-11 |
2026-03-19 |
Novartis Ag |
Antibodies targeting il-31
|
|
CN121896173A
(zh)
|
2024-10-21 |
2026-04-21 |
深圳市湾岛细胞科技有限公司 |
表达外源肌苷单磷酸脱氢酶的真核细胞
|
|
CN120681889B
(zh)
*
|
2025-06-24 |
2025-12-12 |
广东工业大学 |
一种利用微生物菌剂快速降解湖泊水体难降解溶解性有机物的方法
|